FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2213721523> ?p ?o ?g. }

• W2213721523 endingPage "e0145066" @default.
• W2213721523 startingPage "e0145066" @default.
• W2213721523 abstract "Background Tuberculosis is a major public health problem especially in developing countries, the comparative efficacy and safety of fluroquinolones (FQs) for adult patients with newly diagnosed, sputum-positive tuberculosis remains controversial. We aimed to investigate the benefits and risks of FQs-containing (addition/substitution) regimens in this population. Methods A network meta-analysis was performed to compare FQs (C: ciprofloxacin; O: ofloxacin; Lo: levofloxacin; M: moxifloxacin; G: gatifloxacin) addition/substitution regimen with standard HRZE regimen (ie isoniazid, rifampicin, pyrazinamide and ethambutol) in newly diagnosed, sputum-positive tuberculosis. Medline, Embase and Cochrane Central Register of Controlled Trials were systematically searched, randomized trials with duration longer than 8 weeks were included. The primary outcome was week-8 sputum negativity, and secondary outcomes included treatment failure, serious adverse events and death from all cause. Results Twelve studies comprising 6465 participants were included in the network meta-analysis. Löwenstein-Jensen culture method showed that HRZEM (OR 4.96, 95% CI 2.83–8.67), MRZE (OR 1.48, 95% CI 1.19–1.84) and HRZM (OR 1.32, 95% CI 1.08–1.62) had more sputum conversion than HRZE by the eighth week, whereas HRC (OR 0.39, 95% CI 0.19–0.77) and HRZO (OR 0.47, 95% CI 0.24–0.92) were worse than HRZE. Moxifloxacin-containing regimens showed more conversion than HRZE by liquid method at the end of two months. But by the end of treatment, FQs-containing regimens didn’t show superiority than HRZE on treatment failure. There were no significant differences between any regimens on other outcomes like serious adverse events and all-cause death. Conclusion This comprehensive network meta-analysis showed that compared with HRZE, moxifloxacin-containing regimens could significantly increase sputum conversion by the eighth week for patients with newly diagnosed pulmonary tuberculosis while HRC and HRZO regimens were inferior. But all the FQs-containing regimens did not show superiority in other outcomes (such as treatment failure, serious adverse events and all-cause death). Thus, HRZE is still an effective regimen for this population. Although moxifloxacin-containing regimens have deomonstrated their potential, FQs-containing regimens should be used with great caution to avoid widespread FQs-resistance worldwide." @default.
• W2213721523 created "2016-06-24" @default.
• W2213721523 creator A5011698867 @default.
• W2213721523 creator A5022802322 @default.
• W2213721523 creator A5044528533 @default.
• W2213721523 creator A5055814924 @default.
• W2213721523 creator A5073658076 @default.
• W2213721523 creator A5075479756 @default.
• W2213721523 creator A5075736599 @default.
• W2213721523 creator A5089966579 @default.
• W2213721523 date "2015-12-15" @default.
• W2213721523 modified "2023-09-30" @default.
• W2213721523 title "Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis" @default.
• W2213721523 cites W1600946808 @default.
• W2213721523 cites W1965009420 @default.
• W2213721523 cites W1965877207 @default.
• W2213721523 cites W1966126698 @default.
• W2213721523 cites W1970128129 @default.
• W2213721523 cites W1970189825 @default.
• W2213721523 cites W1972176917 @default.
• W2213721523 cites W1973110906 @default.
• W2213721523 cites W1974401710 @default.
• W2213721523 cites W1996896990 @default.
• W2213721523 cites W1996930122 @default.
• W2213721523 cites W2005947177 @default.
• W2213721523 cites W2032342750 @default.
• W2213721523 cites W2037593179 @default.
• W2213721523 cites W2039809703 @default.
• W2213721523 cites W2045299816 @default.
• W2213721523 cites W2048142893 @default.
• W2213721523 cites W2074415800 @default.
• W2213721523 cites W2091808438 @default.
• W2213721523 cites W2095281873 @default.
• W2213721523 cites W2098771520 @default.
• W2213721523 cites W2098923148 @default.
• W2213721523 cites W2102212813 @default.
• W2213721523 cites W2103017208 @default.
• W2213721523 cites W2111276287 @default.
• W2213721523 cites W2114394851 @default.
• W2213721523 cites W2124584779 @default.
• W2213721523 cites W2125648033 @default.
• W2213721523 cites W2131886165 @default.
• W2213721523 cites W2133759445 @default.
• W2213721523 cites W2134527984 @default.
• W2213721523 cites W2134655561 @default.
• W2213721523 cites W2135989318 @default.
• W2213721523 cites W2136204381 @default.
• W2213721523 cites W2140574477 @default.
• W2213721523 cites W2141448586 @default.
• W2213721523 cites W2142363904 @default.
• W2213721523 cites W2148361291 @default.
• W2213721523 cites W2149860604 @default.
• W2213721523 cites W2151109508 @default.
• W2213721523 cites W2153938082 @default.
• W2213721523 cites W2156241117 @default.
• W2213721523 cites W2158409385 @default.
• W2213721523 cites W2160571788 @default.
• W2213721523 cites W2162151914 @default.
• W2213721523 cites W2164920874 @default.
• W2213721523 cites W2169169258 @default.
• W2213721523 cites W2170535863 @default.
• W2213721523 cites W2408006510 @default.
• W2213721523 cites W2422463776 @default.
• W2213721523 cites W2588681363 @default.
• W2213721523 cites W89947807 @default.
• W2213721523 doi "https://doi.org/10.1371/journal.pone.0145066" @default.
• W2213721523 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4682926" @default.
• W2213721523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26669635" @default.
• W2213721523 hasPublicationYear "2015" @default.
• W2213721523 type Work @default.
• W2213721523 sameAs 2213721523 @default.
• W2213721523 citedByCount "18" @default.
• W2213721523 countsByYear W22137215232016 @default.
• W2213721523 countsByYear W22137215232017 @default.
• W2213721523 countsByYear W22137215232018 @default.
• W2213721523 countsByYear W22137215232019 @default.
• W2213721523 countsByYear W22137215232020 @default.
• W2213721523 countsByYear W22137215232022 @default.
• W2213721523 crossrefType "journal-article" @default.
• W2213721523 hasAuthorship W2213721523A5011698867 @default.
• W2213721523 hasAuthorship W2213721523A5022802322 @default.
• W2213721523 hasAuthorship W2213721523A5044528533 @default.
• W2213721523 hasAuthorship W2213721523A5055814924 @default.
• W2213721523 hasAuthorship W2213721523A5073658076 @default.
• W2213721523 hasAuthorship W2213721523A5075479756 @default.
• W2213721523 hasAuthorship W2213721523A5075736599 @default.
• W2213721523 hasAuthorship W2213721523A5089966579 @default.
• W2213721523 hasBestOaLocation W22137215231 @default.
• W2213721523 hasConcept C126322002 @default.
• W2213721523 hasConcept C141071460 @default.
• W2213721523 hasConcept C142724271 @default.
• W2213721523 hasConcept C197934379 @default.
• W2213721523 hasConcept C2776228421 @default.
• W2213721523 hasConcept C2776301714 @default.
• W2213721523 hasConcept C2777025531 @default.
• W2213721523 hasConcept C2777107064 @default.
• W2213721523 hasConcept C2777653605 @default.
• W2213721523 hasConcept C2777975735 @default.

• next